Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in Rheumatoid Arthritis Inadequately Controlled With Biologics
NCT02434757Unknown
- Sponsor
- Ronald J. Rapoport
- Start
- Feb 2014
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of repository corticotropin injection in rheumatoid arthritis (RA), sponsored by Ronald J. Rapoport. Primary endpoints: Disease Activity Score in 28 joints reduction >1.2 points at 12 weeks and American College of Rheumatology 20/50/70 Improvement Criteria at 12 weeks. Status: unknown.
02
Drugs
repository corticotropin injection
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02434757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434757.